Physician profile
Mary Damore
NPI 1447250287
$4,051.21
in general payments reported to CMS, 2019-2025
33 companies · $801 in 2025
The $801 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $206 · 2021: $134 · 2022: $620 · 2023: $941 · 2024: $1,037 · 2025: $801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,778.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $516.41 | 2019-2025 | Synthroid, Lupron Depot |
| Ascendis Pharma Endocrinology INC | $473.50 | 2022-2025 | Skytrofa |
| Novo Nordisk INC | $407.31 | 2020-2025 | Sogroya, Norditropin |
| Biomarin Pharmaceutical INC. | $397.13 | 2022-2024 | Voxzogo 1.2mg |
| Insulet Corporation | $363.49 | 2019-2025 | Omnipod, Omnipod |
| Sanofi-Aventis U.S. LLC | $314.88 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $150.82 | 2022-2025 | Strensiq |
| Lilly USA, LLC | $145.61 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $108.13 | 2021-2025 | Unithroid |
| Dexcom, INC. | $96.56 | 2020-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $94.58 | 2023-2025 | Freestyle Libre |
| Azurity Pharmaceuticals, INC. | $93.86 | 2023-2025 | Triptodur, Triptodur |
| Neurocrine Biosciences, INC. | $93.44 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $92.61 | 2020-2024 | Gvoke Hypopen |
| Pfizer INC. | $87.61 | 2022-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar Pharmaceuticals, INC. | $61.14 | 2022 | |
| Kyowa Kirin, INC. | $56.35 | 2025 | |
| Beta Bionics, INC. | $55.15 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Endo USA, INC. | $53.19 | 2024-2025 | Supprelin |
| Arbor Pharmaceuticals, INC. | $50.50 | 2019-2021 | |
| Eton Pharmaceuticals, INC. | $43.21 | 2023 | Alkindi |
| Tandem Diabetes Care, INC. | $36.51 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Ibsa Pharma INC. | $35.89 | 2019-2024 | Licart, Tirosint |
| Soleno Therapeutics, INC. | $35.11 | 2025 | Vykat Xr |
| Endo Pharmaceuticals INC. | $26.88 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $25.60 | 2020 | |
| Companion Medical, INC. | $25.07 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.35 | 2024 | Eohilia |
| Tolmar, INC. | $22.17 | 2023 | |
| Medtronic, INC. | $21.40 | 2021 | |
| Intuity Medical INC | $17.19 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $14.86 | 2019 | |
| Medtronic Minimed, INC. | $12.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Damore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.